- Joined
- Apr 15, 2012
- Messages
- 14,747
The researchers also performed stratified analyses based on cumulative TNF-alpha antagonist dose and time since first TNF-alpha antagonist dose, but found no association with cancer risk. Their analysis also did not find an increased risk by cancer type.
However, he added, the IBD drugs azathioprine and 6-mercaptopurine have clearly been linked to cancer. "They are unequivocally linked with a higher risk of non-melanoma skin cancer and a higher risk of non-Hodgkin lymphoma," Dr. Sandborn said.
Studies have shown that combination therapy with azathioprine and TNF-alpha antagonists is more effective than either drug given as monotherapy, he added. The question that needs to be answered, he said, is how the benefit of combination therapy compares to the increased cancer risk seen with azathioprine. "I hope the authors will continue to mine their data to further explore the relationship of the whole range of drugs we use in IBD and cancer," he said.
From:
http://www.medscape.com/viewarticle/826945?src=wnl_edit_tpal&uac=185734DZ